PMID- 27236110
OWN - NLM
STAT- MEDLINE
DCOM- 20170811
LR  - 20220408
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 218
DP  - 2016 Sep 1
TI  - Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 
      diabetes and end-stage renal disease.
PG  - 170-175
LID - S0167-5273(16)30970-6 [pii]
LID - 10.1016/j.ijcard.2016.05.062 [doi]
AB  - BACKGROUND: Recent clinical trials have evaluated the cardiovascular outcomes of 
      dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes 
      mellitus (T2DM), but those with end-stage renal disease (ESRD) were ineligible 
      for participation in these trials. We aimed to characterize the impact of DPP-4 
      inhibitors on major adverse cardiovascular events (MACEs) in patients with T2DM 
      and ESRD undergoing chronic dialysis. METHODS: This nationwide observational 
      study utilized data from 3556 patients aged >/=20years with T2DM and ESRD who 
      initiated treatment with DPP-4 inhibitors between 1 March 2009 and 31 June 2013, 
      retrieved from Taiwan's National Health Insurance Research Database. Each DPP-4 
      inhibitor user was matched to a non-user control subject using propensity scores. 
      The primary outcomes were all-cause mortality and MACEs (ischemic stroke and 
      myocardial infarction). The secondary outcomes were hospitalization for heart 
      failure and hypoglycemia. All subjects were followed until death or 31 December 
      2013. RESULTS: Compared with non-users, DPP-4 inhibitor users had lower risks of 
      all-cause mortality (hazard ratio [HR] 0.43, 95% confidence interval [CI] 
      0.39-0.47), MACEs (HR 0.76, 95% CI 0.65-0.90), and ischemic stroke (HR 0.77, 95% 
      CI 0.61-0.97); the risks of myocardial infarction and hospitalization for heart 
      failure and hypoglycemia did not differ. This treatment effect remained 
      consistent in subgroup analyses according to age, sex, comorbidities, dialysis 
      modality, and insulin use. CONCLUSIONS: In this nationwide ESRD cohort, DPP-4 
      inhibitor use was associated with reduced risks of all-cause mortality and 
      ischemic stroke.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Chan, Shang-Yih
AU  - Chan SY
AD  - Division of Cardiology, Department of Medicine, Taipei City Hospital, Heping, 
      Fuyou Branch, Taipei, Taiwan.
FAU - Ou, Shuo-Ming
AU  - Ou SM
AD  - Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, 
      Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, 
      Taipei, Taiwan.
FAU - Chen, Yung-Tai
AU  - Chen YT
AD  - Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, 
      Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, 
      Taiwan; Division of Nephrology, Department of Medicine, Taipei City Hospital, 
      Heping, Fuyou Branch, Taipei, Taiwan. Electronic address: ytchen0117@gmail.com.
FAU - Shih, Chia-Jen
AU  - Shih CJ
AD  - School of Medicine, National Yang-Ming University, Taipei, Taiwan; Department of 
      Medicine, Taipei Veterans General Hospital, Yuanshan Branch, Yilan, Taiwan; Deran 
      Clinic, Yilan, Taiwan. Electronic address: b001089010@tmu.edu.tw.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20160514
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
SB  - IM
MH  - Aged
MH  - Cardiovascular Diseases/*epidemiology/mortality
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Female
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Kidney Failure, Chronic/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Propensity Score
MH  - Taiwan
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Dipeptidyl peptidase-4 inhibitor
OT  - End-stage renal disease
OT  - Major adverse cardiovascular events
OT  - Mortality
EDAT- 2016/05/29 06:00
MHDA- 2017/08/12 06:00
CRDT- 2016/05/29 06:00
PHST- 2016/04/18 00:00 [received]
PHST- 2016/05/12 00:00 [accepted]
PHST- 2016/05/29 06:00 [entrez]
PHST- 2016/05/29 06:00 [pubmed]
PHST- 2017/08/12 06:00 [medline]
AID - S0167-5273(16)30970-6 [pii]
AID - 10.1016/j.ijcard.2016.05.062 [doi]
PST - ppublish
SO  - Int J Cardiol. 2016 Sep 1;218:170-175. doi: 10.1016/j.ijcard.2016.05.062. Epub 
      2016 May 14.